Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors

Clinical Cancer Research

Volumn 19, Issue 6, 2013, Pages 1512-1524

  Schott, Anne F ^a   Landis, Melissa D ^b   Dontu, Gabriela ^c   Griffith, Kent A ^a   Layman, Rachel M ^d   Krop, Ian ^e   Paskett, Lacey A ^b   Wong, Helen ^b   Dobrolecki, Lacey E ^b   Lewis, Michael T ^b   Froehlich, Amber M ^b   Paranilam, Jaya ^b   Hayes, Daniel F ^a   Wicha, Max S ^a   Chang, Jenny C ^b,f  

^a UNIVERSITY OF MICHIGAN   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d OHIO STATE UNIVERSITY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; DOCETAXEL; GAMMA SECRETASE INHIBITOR; HERMES ANTIGEN; MK 0752; MRK 003; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER GRAFT; CANCER STEM CELL; CLINICAL ARTICLE; CONSTITUTIONAL SYMPTOM; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EYE DISEASE; EYE TOXICITY; FEASIBILITY STUDY; FEMALE; FOOT AND MOUTH DISEASE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOPATHOLOGY; INFECTION; LIVER FUNCTION TEST; LUNG TOXICITY; LYMPHATIC SYSTEM DISEASE; MALE; METABOLIC DISORDER; MOUSE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN TOXICITY; SOFT TISSUE DISEASE; SYMPTOM; VISUAL IMPAIRMENT;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENE DERIVATIVES; BREAST NEOPLASMS; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MICE; NEOPLASM STAGING; PROPIONATES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SULFONES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875168492     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3326     Document Type: Article

References (29)

1. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005;23:1169-77.
2. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene 2004;23:7274-82.
3. Farnie G, Clarke RB. Mammary stem cells and breast cancer - role of Notch signalling. Stem Cell Rev 2007;3:169-75.
4. Song LL, Miele L. Cancer stem cells - an old idea that's new again: implications for the diagnosis and treatment of breast cancer. Expert Opin Biol Ther 2007;7:431-8.
5. Weng AP, Ferrando AA, Lee W, Morris J IV, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71.
6. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004;167:215-21.
7. van Es JH, van Gijn ME, Riccio O, van den Born M, VooijsM, Begthel H, et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435:959-63.
8. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene 2008;27:5124-31.
9. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999;284:770-6.
10. Smith GH, Gallahan D, Diella F, Jhappan C, Merlino G, Callahan R. Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development. Cell Growth Differ 1995;6:563-77.
11. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG, et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007;99:616-27.
12. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
13. Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol 2000;228:151-65.
14. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007;28:339-63.
15. Kopan R, Ilagan MXG. Gamma-secretase: proteasome of the membrane? Nat Rev Mol Cell Biol 2004;5:499-504.
16. Miele L. Notch signaling. Clin Cancer Res 2006;12:1074-9.
17. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 2011;29:3529-34.
18. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol 2012;30:2307-13.
19. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65: 5506-11.
20. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9.
21. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
22. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
23. Dontu G, Wicha MS. Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia 2005;10:75-86.
24. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67.
25. DeOme KB, Medina D. A new approach to mammary tumorigenesis in rodents. Cancer 1969;24:1255-8.
26. Dave B, Landis MD, Tweardy DJ, Chang JC. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human xenograft model. PLoS ONE 2012;7:e30207.
27. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77.
28. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010;70:709-18.
29. Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011;29:2144-9.